BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 28291580)

  • 1. Restored Plasma Anandamide and Endometrial Expression of Fatty Acid Amide Hydrolase in Women With Polycystic Ovary Syndrome by the Combination Use of Diane-35 and Metformin.
    Cui N; Feng X; Zhao Z; Zhang J; Xu Y; Wang L; Hao G
    Clin Ther; 2017 Apr; 39(4):751-758. PubMed ID: 28291580
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decreased expression of fatty acid amide hydrolase in women with polycystic ovary syndrome.
    Cui N; Yang Y; Xu Y; Zhang J; Jiang L; Hao G
    Gynecol Endocrinol; 2017 May; 33(5):368-372. PubMed ID: 28132572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of polycystic ovarian syndrome with Diane-35 or Diane-35 plus metformin.
    Feng W; Jia YY; Zhang DY; Shi HR
    Gynecol Endocrinol; 2016; 32(2):147-50. PubMed ID: 26507097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The platelet activating factor acetyl hydrolase, oxidized low-density lipoprotein, paraoxonase 1 and arylesterase levels in treated and untreated patients with polycystic ovary syndrome.
    Carlioglu A; Kaygusuz I; Karakurt F; Gumus II; Uysal A; Kasapoglu B; Armutcu F; Uysal S; Keskin EA; Koca C
    Arch Gynecol Obstet; 2014 Nov; 290(5):929-35. PubMed ID: 24840107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined use of Diane-35 and metformin improves the ovulation in the PCOS rat model possibly via regulating glycolysis pathway.
    Zhang S; Tu H; Yao J; Le J; Jiang Z; Tang Q; Zhang R; Huo P; Lei X
    Reprod Biol Endocrinol; 2020 Jun; 18(1):58. PubMed ID: 32493421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic profile of Diane-35 versus Diane-35 plus metformin in Chinese PCOS women under standardized life-style changes.
    Wu H; Ruan X; Jin J; Mueck AO
    Gynecol Endocrinol; 2015 Jul; 31(7):548-51. PubMed ID: 26004979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endocannabinoid system activation may be associated with insulin resistance in women with polycystic ovary syndrome.
    Juan CC; Chen KH; Wang PH; Hwang JL; Seow KM
    Fertil Steril; 2015 Jul; 104(1):200-6. PubMed ID: 25935491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diane-35 and Metformin Induce Autophagy and Apoptosis in Polycystic Ovary Syndrome Women with Early-Stage Endometrial Carcinoma.
    Liu Y; Wang Y; Yao D; Chen X; Zhang F; Feng Y; Li X
    Genes (Basel); 2022 Jan; 13(1):. PubMed ID: 35052471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study.
    Morin-Papunen LC; Vauhkonen I; Koivunen RM; Ruokonen A; Martikainen HK; Tapanainen JS
    J Clin Endocrinol Metab; 2000 Sep; 85(9):3161-8. PubMed ID: 10999803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Diane-35, alone or in combination with orlistat or metformin in Chinese polycystic ovary syndrome patients.
    Ruan X; Song J; Gu M; Wang L; Wang H; Mueck AO
    Arch Gynecol Obstet; 2018 Jun; 297(6):1557-1563. PubMed ID: 29602978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum uric acid concentration as non-classic cardiovascular risk factor in women with polycystic ovary syndrome: effect of treatment with ethinyl-estradiol plus cyproterone acetate versus metformin.
    Luque-Ramírez M; Alvarez-Blasco F; Uriol Rivera MG; Escobar-Morreale HF
    Hum Reprod; 2008 Jul; 23(7):1594-601. PubMed ID: 18375410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of Chinese patent medicine Tian Gui Capsule in patients with polycystic ovary syndrome: a randomized controlled trial.
    Kuek S; Wang WJ; Gui SQ
    Zhong Xi Yi Jie He Xue Bao; 2011 Sep; 9(9):965-72. PubMed ID: 21906521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of ethinyl-estradiol plus cyproterone acetate versus metformin effects on classic metabolic cardiovascular risk factors in women with the polycystic ovary syndrome.
    Luque-Ramírez M; Alvarez-Blasco F; Botella-Carretero JI; Martínez-Bermejo E; Lasunción MA; Escobar-Morreale HF
    J Clin Endocrinol Metab; 2007 Jul; 92(7):2453-61. PubMed ID: 17426085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of metformin versus ethinyl-estradiol plus cyproterone acetate on ambulatory blood pressure monitoring and carotid intima media thickness in women with the polycystic ovary syndrome.
    Luque-Ramírez M; Mendieta-Azcona C; Alvarez-Blasco F; Escobar-Morreale HF
    Fertil Steril; 2009 Jun; 91(6):2527-36. PubMed ID: 18565522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of Diane-35 and metformin in treatment of polycystic ovary syndrome: an updated systematic review.
    Jing Z; Liang-Zhi X; Tai-Xiang W; Ying T; Yu-Jian J
    Gynecol Endocrinol; 2008 Oct; 24(10):590-600. PubMed ID: 19012104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How medical treatment affects mean platelet volume as a cardiovascular risk marker in polycystic ovary syndrome?
    Kabil Kucur S; Gozukara I; Aksoy A; Uludag EU; Keskin H; Kamalak Z; Carlioglu A
    Blood Coagul Fibrinolysis; 2015 Dec; 26(8):862-5. PubMed ID: 25402193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between CD16
    Tang L; Ye J; Shi Y; Zhu X
    Int J Gynaecol Obstet; 2019 Apr; 145(1):12-17. PubMed ID: 30710445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased body iron stores of obese women with polycystic ovary syndrome are a consequence of insulin resistance and hyperinsulinism and are not a result of reduced menstrual losses.
    Luque-Ramírez M; Alvarez-Blasco F; Botella-Carretero JI; Sanchón R; San Millán JL; Escobar-Morreale HF
    Diabetes Care; 2007 Sep; 30(9):2309-13. PubMed ID: 17536071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of ethinyl estradiol-cyproterone acetate treatment on asymmetric dimethyl-arginine levels in women with polycystic ovary syndrome.
    Karakurt F; Carlioglu A; Kaygusuz I; Gumus II; Uz B; Akdeniz D
    Arch Gynecol Obstet; 2014 Jan; 289(1):135-40. PubMed ID: 23880889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of a low-dose estrogen-antiandrogen combination (Diane-35) on clinical signs of androgenization, hormone profile and ovarian size in patients with polycystic ovary syndrome.
    Prelević GM; Würzburger MI; Balint-Perić L; Puzigaća Z
    Gynecol Endocrinol; 1989 Dec; 3(4):269-80. PubMed ID: 2516704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.